BriaCell Therapeutics Bolsa (NASDAQ: BCTX)

Últimas noticias sobre BriaCell Therapeutics (NASDAQ:BCTX) Bolsa

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

News

CVNA

Carvana Announces Integration Of Auction And Reconditioning 'Megasite' In Central New Jersey To Boost Capacity

<p><strong>Super Micro Computer, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has reportedly become the second most shorted&nbsp;in the technology hardware and&nbsp;equipment industry.</p>
<p><strong>What Happened</strong>: <strong>S3 Partners</strong> has found that 22.3% of Super Micro&#8217;s floating shares are shorted, a short interest valued at $3.89 billion. According to <strong>Ihor Dusaniwsky</strong>, S3&#8217;s Managing Director, short sellers have augmented their positions by 38% this year, incorporating shares worth $1.1 billion, <a href="https://fortune.com/2025/04/01/supermicro-general-counsel-audit-accounting-investigation-short-seller-stock-profit-ai/">reported</a> Fortune</p>
<p>"Shorting SMCI has not been a profitable trade for the full year, but recently it has been very profitable," stated Dusaniwsky. In the past month alone, short sellers have added 10.7 million shares, a 10% increase in total shares shorted. Despite a year-to-date loss of $263 million, short sellers managed to earn $7 million in profits in March, marking an 18.2% return.</p>
<p>Meanwhile, on Monday, Super Micro Computer appointed <strong>Yitai Hu</strong> as General Counsel &amp; Senior Vice President, Corporate Development, following a board recommendation from an independent investigation into management and accounting practices. The move is part of the company's efforts to improve internal functions and ensure continued compliance. </p>
<p><strong>See Also:</strong> <a href="https://benzinga.com/tech/25/04/44600131/intels-stock-plummeted-50-in-past-12-months-now-the-lip-bu-tan-led-company-is-betting-on-18a-chip-breakthrough-were-freezing-it" target="_blank" rel="noreferrer noopener">Intel&#8217;s Stock Plummeted 50% In Past 12 Months, Now The Lip-Bu Tan-Led Company Is Betting On 18A Chip Breakthrough: &#8216;We&#8217;re Freezing It&#8217;</a></p>
<p><strong>Why It Matters</strong>: Super Micro and CEO <strong>Charles Liang</strong> are still dealing with the repercussions of their accounting issues, facing multiple lawsuits and investigations from the Department of Justice (DoJ) and the Securities and Exchange Commission (SEC).</p>
<p>Despite the financial challenges, Liang remains hopeful of a turnaround. Super Micro has confirmed its cooperation with the regulators and the company has recently issued financial filings after months of delay, which Liang considers a significant milestone. The firm aims to meet&nbsp;a $40 billion revenue target&nbsp;by 2025. </p>
<p>Super Micro&#8217;s current predicament comes on the heels of a&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44459593/super-micro-computer-feels-the-heat-from-competitors-customers-supplies-this-analyst-turns-bearish">downgrade</a>&nbsp;from Goldman Sachs in late March. Analyst <strong>Michael Ng</strong> downgraded the rating for Super Micro Computer from Neutral to Sell, while reducing the price target from $40 to $32. He cited downside risks on valuation, competition, and gross margins as the reasons for the downgrade. This bearish outlook, coupled with the company&#8217;s ongoing accounting issues, has likely contributed to the surge in short interest.</p>
<p>Super Micro Computer stock rose 2.37% to close at $35.05 on Tuesday. The stock lost nearly 17% over the past 6 months.</p>
<ul>
<li><strong>Read Next:</strong>&nbsp;<a href="https://benzinga.com/news/25/03/44575557/mark-cuban-says-if-they-replaced-elon-musk-with-him-hes-still-try-to-make-government-smaller-by-cutting-a-lo" target="_blank" rel="noreferrer noopener">Mark Cuban Says, If They Replaced Elon Musk With Him, He&#8217;s Still Try to Make Government Smaller By &#8216;Cutting A Lot Of People&#8217;</a></li>
</ul>
<p><em>Image via Shutterstock</em></p>
<p><strong><em>Disclaimer:&nbsp;</em></strong><em>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>


Equities

General

AVGO

INTC

SMCI

Super Micro's Short Position Hits Nearly $4 billion Amid 'Very Profitable' Trades In Recent Times: Report

<p>8 analysts have expressed a variety of opinions on D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $9.38, with a high estimate of $12.00 and a low estimate of $8.00. Observing a 16.38% increase, the current average has risen from the previous average price target of $8.06. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595272_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of D-Wave Quantum by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to D-Wave Quantum. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of D-Wave Quantum compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of D-Wave Quantum's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into D-Wave Quantum's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QBTS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on D-Wave Quantum analyst ratings.</strong></a></p>
<h2>Discovering D-Wave Quantum: A Closer Look</h2>
<p>D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.</p>
<h3>D-Wave Quantum: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, D-Wave Quantum faced challenges, resulting in a decline of approximately <strong>-20.54%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> D-Wave Quantum's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-3727.89%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> D-Wave Quantum's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-376.45%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-69.02%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.61</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

QBTS

Analyst Expectations For D-Wave Quantum's Future

<p>Needham  analyst Kyle Peterson   maintains Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) with a Buy and lowers the price target from $7 to $2.</p>


Price Target

LPRO

Needham Maintains Buy on Open Lending, Lowers Price Target to $2

<p>During the last three months, 9 analysts shared their evaluations of Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.89, a high estimate of $25.00, and a low estimate of $15.00. This current average reflects an increase of 11.89% from the previous average price target of $18.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595253_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Magnite. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$22.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Magnite. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Magnite compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Magnite's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Magnite's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGNI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Magnite analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Magnite</h2>
<p>Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.</p>
<h3>Magnite: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Magnite showcased positive performance, achieving a revenue growth rate of <strong>3.76%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Magnite's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>18.77%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Magnite's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.87%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Magnite's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.3%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.79</strong>, Magnite adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MGNI

Beyond The Numbers: 9 Analysts Discuss Magnite Stock

<p>Analysts' ratings for CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.83, along with a high estimate of $42.00 and a low estimate of $30.00. This upward trend is apparent, with the current average reflecting a 7.92% increase from the previous average price target of $33.20.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595240_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of CenterPoint Energy among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CenterPoint Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CenterPoint Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of CenterPoint Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CenterPoint Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CenterPoint Energy analyst ratings.</strong></a></p>
<h2>Discovering CenterPoint Energy: A Closer Look</h2>
<p>CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.</p>
<h3>CenterPoint Energy's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> CenterPoint Energy's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>3.67%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> CenterPoint Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>10.96%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.34%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> CenterPoint Energy's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.57%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.97</strong>, CenterPoint Energy adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On CenterPoint Energy Through 6 Analysts

<p>HT-ALZ, a proprietary formulation of an FDA-approved NK-1 receptor antagonist, has shown&nbsp;significant cognitive and behavioral benefits&nbsp;in APP/PS1 mouse models of Alzheimer's disease. The study demonstrated that chronic oral administration of HT-ALZ led to&nbsp;marked improvement in memory, reduction of anxiety-like behavior, and enhanced sensorimotor gating, all without impairing motor function.</p>


HOTH

Hoth Therapeutics Reports Preclinical Data On Lead Alzheimer's Candidate, HT-ALZ; Says Results Underscore Dual-Action Profile Of HT-ALZ—Impacting Both Pathology And Symptomology

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Viant Technology, revealing an average target of $23.14, a high estimate of $27.00, and a low estimate of $21.00. Surpassing the previous average price target of $22.14, the current average has increased by 4.52%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595231_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Viant Technology by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Condon</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Viant Technology. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viant Technology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Viant Technology's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Viant Technology's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DSP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Viant Technology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Viant Technology</h2>
<p>Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.</p>
<h3>Key Indicators: Viant Technology's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Viant Technology's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>39.82%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>1.94%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Viant Technology's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.08%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Viant Technology's ROA excels beyond industry benchmarks, reaching <strong>0.4%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.48</strong>, Viant Technology adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 7 Analyst Ratings Have To Say About Viant Technology

<p>Analysts' ratings for Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $21.38, a high estimate of $26.00, and a low estimate of $17.00. A 3.91% drop is evident in the current average compared to the previous average price target of $22.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595223_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Levi Strauss is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Levi Strauss. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Levi Strauss compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Levi Strauss's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Levi Strauss's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LEVI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Levi Strauss analyst ratings.</strong></a></p>
<h2>About Levi Strauss</h2>
<p>Levi Strauss &amp; Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss &amp; Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.</p>
<h3>Key Indicators: Levi Strauss's Financial Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Levi Strauss showcased positive performance, achieving a revenue growth rate of <strong>12.02%</strong> as of 30 November, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Levi Strauss's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.93%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Levi Strauss's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.5%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Levi Strauss's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.89%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.12</strong>, Levi Strauss adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LEVI

Where Levi Strauss Stands With Analysts

<p>Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $15.56, with a high estimate of $20.00 and a low estimate of $8.00. A 5.35% drop is evident in the current average compared to the previous average price target of $16.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743595215_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Macy's by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macy's. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macy's compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Macy's's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Macy's's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/M/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Macy's analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Macy's</h2>
<p>Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.</p>
<h3>Financial Insights: Macy's</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Macy's faced challenges, resulting in a decline of approximately <strong>-4.39%</strong> in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Macy's's net margin excels beyond industry benchmarks, reaching <strong>4.27%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.86%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.03%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.25</strong>, Macy's adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Macy's: 9 Analysts Share Their Views

<p>Needham  analyst Laura Martin   reiterates Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy and maintains $21 price target.</p>


Reiteration

Needham Reiterates Buy on Viant Technology, Maintains $21 Price Target

<p>JP Morgan  analyst Jimmy Bhullar   upgrades Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) from Neutral to Overweight and raises the price target from $232 to $237.</p>


Upgrades

JP Morgan Upgrades Reinsurance Gr to Overweight, Raises Price Target to $237

<p>Needham  analyst Mike Cikos   reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $28 price target.</p>


CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $28 Price Target

<p>Needham  analyst Laura Martin   reiterates Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and maintains $20 price target.</p>


Needham Reiterates Buy on Magnite, Maintains $20 Price Target

<p>Jones Trading  analyst Justin Walsh   downgrades Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) from Buy to Hold.</p>


Downgrades

MNPR

Jones Trading Downgrades Monopar Therapeutics to Hold

<p>Needham  analyst Mayank Tandon   maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Buy and lowers the price target from $45 to $28.</p>


NCNO

Needham Maintains Buy on Ncino, Lowers Price Target to $28

<p>Jones Trading  analyst Justin Walsh   downgrades BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) from Buy to Hold.</p>


BLRX

Jones Trading Downgrades BioLine Rx to Hold

<p>HC Wainwright &amp; Co.  analyst Ed Arce   reiterates Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) from Neutral to Neutral.</p>


GALT

HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

<p>Jefferies  analyst Ashley Helgans   maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Hold and lowers the price target from $101 to $80.</p>


Comments

BriaCell Therapeutics

Noticias

Últimas noticias sobre BriaCell Therapeutics (NASDAQ:BCTX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL